In situ hybridization experiments were performed in rat brain sections from normal and 6-hydroxydopamine-treated rats in order to map and identify the neurons expressing the DI receptor gene in the striatum and the substantia nigra. Procedures of combined in situ hybridization, allowing the simultaneous detection of two mRNAs in the same section or in adjacent sections, were used to characterize the phenotypes of the neurons expressing the DI receptor gene. DI receptor mRNA was found in neurons all over the caudateputamen, the accumbens nucleus, and the olfactory tubercle but not in the substantia nigra. In the caudate-putamen and accumbens nucleus, most of the neurons containing DI receptor mRNA were characterized as medium-sized substance P neurons and distinct from those containing D2 receptor mRNA. The basal ganglia are known to be involved in the control of several important behavioral and motor functions. The striatum, which constitutes one of the main components of the basal ganglia, is characterized by a particularly complex anatomical and cellular organization that includes an important neurochemical diversity in term of neurotransmitters and related receptors, differentially distributed and organized inside two distinct compartments, the striosomes (or patches) and the matrix receiving distinct neuronal inputs (1-3). The striatum is under the influence of several inputs (including the glutamatergic corticostriatal pathway), among which is the dopaminergic mesostriatal pathway, which exerts profound and complex influences on target neurons (1, 4-7). Dopamine is known to act in the striatum through at least two distinct receptor types, D1 and D2, which differ by their transduction mechanisms and their pharmacological properties: the D1 dopamine receptor is positively coupled to adenylate cyclase, whereas the D2 receptor is not or is negatively coupled to this enzyme (8, 9). There is a predominant presence of D1 and D2 receptors in the striatum (10, 11) and they interact to control striatal functions (12). They are targets for many neuroactive drugs including neuroleptics. In addition, perturbations of dopamine transmission may contribute to severe neuropsychiatric disorders (13).
receptor mRNA was found in neurons all over the caudateputamen, the accumbens nucleus, and the olfactory tubercle but not in the substantia nigra. In the caudate-putamen and accumbens nucleus, most of the neurons containing DI receptor mRNA were characterized as medium-sized substance P neurons and distinct from those containing D2 receptor mRNA. Nevertheless, 15-20% of the substance P neurons did not contain DI receptor mRNA. The neurons containing preproenkephalin A mRNA did not contain DI receptor mRNA but contained D2 receptor mRNA. A small number of cholinergic and somatostatinergic neurons exhibited a weak reaction for DI receptor mRNA. These results demonstrate that dopamine acts on efferent striatal neurons through expression of distinct receptors-namely, DI and D2 in separate cell populations (substance P and preproenkephalin A neurons, respectively)-and can also act on nonprojecting neurons through DI receptor expression.
The basal ganglia are known to be involved in the control of several important behavioral and motor functions. The striatum, which constitutes one of the main components of the basal ganglia, is characterized by a particularly complex anatomical and cellular organization that includes an important neurochemical diversity in term of neurotransmitters and related receptors, differentially distributed and organized inside two distinct compartments, the striosomes (or patches) and the matrix receiving distinct neuronal inputs (1) (2) (3) . The striatum is under the influence of several inputs (including the glutamatergic corticostriatal pathway), among which is the dopaminergic mesostriatal pathway, which exerts profound and complex influences on target neurons (1, (4) (5) (6) (7) . Dopamine is known to act in the striatum through at least two distinct receptor types, D1 and D2, which differ by their transduction mechanisms and their pharmacological properties: the D1 dopamine receptor is positively coupled to adenylate cyclase, whereas the D2 receptor is not or is negatively coupled to this enzyme (8, 9) . There is a predominant presence of D1 and D2 receptors in the striatum (10, 11) and they interact to control striatal functions (12) . They are targets for many neuroactive drugs including neuroleptics. In addition, perturbations of dopamine transmission may contribute to severe neuropsychiatric disorders (13) .
In view of these data, it is important to establish the topological basis of dopamine receptor action in the striatum and especially to determine the nature and the spatial relationships of the target neurons in which they are present. The recent cloning of several dopamine receptors, D1, D2, and D3, all belonging to a same family and coupled to guanine nucleotide-binding proteins (14) (15) (16) (17) (18) (19) , now allows the use of in situ hybridization to identify and map the neurons that express dopamine receptor genes. We have recently demonstrated that the D2 receptor gene is expressed in the striatum within two cell populations: neurons producing enkephalins and acetylcholine neurons (20, 21) . We describe here the topography and the phenotypes of the neurons expressing the D1 receptor gene in the striatum. We demonstrate that D1 and D2 receptor genes are expressed in distinct neuronal subsets and that D1 receptor gene is predominantly expressed in neurons containing substance P as neurotransmitter.
MATERIALS AND METHODS
Tissue Preparation. Brain sections were obtained from adult male rats (Wistar, Iffa Credo, L'Arbresle, France) as described (22) . Brains, fixed with 1% formaldehyde, were cut in a cryostat into 10-,m-or 3-,um-thick serial frontal sections, collected on gelatin-coated slides, and stored at -80°C until use. The 3-,um sections were indexed by pairs of adjacent sections. Most investigations were performed in normal adult rats. In addition, rats having a 6-hydroxydopamine lesion of the substantia nigra were especially used to detect preproenkephalin A (PPA) mRNA with a biotinylated probe. Indeed, substantia nigra lesion increases PPA mRNA content in striatal neurons (23) and then facilitates its detection with nonradioactive in situ hybridization. Sections taken from these animals were used for the simultaneous detection of PPA and dopamine receptor mRNAs (see below).
Probe Preparation and Labeling. The D1 probe was a 45-base synthetic oligonucleotide (5'-GGTGGTCTGGCAA-TTCTTGGCGTGGACTGCTGCCCTCTCCAAGGC-3') corresponding to the third intracytoplasmic domain of the receptor and selected on the basis of the cloned cDNA sequence (17) . This oligonucleotide has no significant homology with the D2 receptor cDNA or other receptor cDNAs of the same family. The D2 probe was a mixture of three 45-base synthetic oligonucleotides as described (20, 21) . The substance P (5'-CCGTTTGCCCATCAATCCAAAGAACTGC-TGAGGCTTGGGTCTCCG-3') and somatostatin (5'-CCAGAAGAAGTTCTTGCAGCCAGCTTTGCGTTC-CCGGGGTGCCAT-3') probes were two 45-base synthetic oligonucleotides selected on the basis of the published sequences (24, 25 the enkephalin precursor, was a double-stranded cDNA used in previous studies (20, 26) . Oligonucleotide probes were labeled using terminal transferase (Amersham) with incor-
) (New England Nuclear) for D1, D2, substance P, and somatostatin probes or biotin-11-dUTP (Enzo Biochem) for somatostatin probe, as described (27) . The doublestranded PPA cDNA was labeled by the -nick-translation procedure with incorporation of dATP[a-35S] or biotin-lidUTP as described (20) .
In Situ Hybridization Procedure and Signal Detection. DI receptor mRNA detection. In situ hybridization with 35S-labeled probes was performed as described (20, 21) with 0.1 ng of D1 probe per slide. Briefly, the slides were hybridized overnight at 40°C, rinsed, dried, and exposed in contact with x-ray film for 5 days. Then they were coated with Ilford K5 emulsion, exposed 3-8 weeks, processed for development, and stained with toluidine blue. Controls for specificity ofthe D1 receptor mRNA detection were performed by addition of D1 unlabeled probe or unrelated unlabeled probes (D2 receptor, vasopressin) to the hybridization medium as described for other controls (27) .
Comparative localization of two mRNAs by hybridization on paired 3-pm-thick sections. Each of two 3-pum adjacent sections was treated with either 35S-labeled D1 probe (0.1 ng) or with 35S-labeled D2, substance P, somatostatin (0.1 ng), or PPA (1 ng) probe. The neurons present on both paired sections were identified after toluidine blue staining with a double microscopic system coupled to an image analyzer (Histo 200, Biocom, Paris).
Comparative localization of two mRNAs by combined hybridization with radioactive and biotinylated probes. Tenmicrometer-thick sections were processed according to an original two-step procedure (unpublished data). Briefly, the sections were hybridized with D1 or D2 radioactive probe (0.1 ng of probe per slide), as described above, and coated with emulsion. After the appropriate time, they were developed, fixed, rinsed in distilled water, immediately immersed in prehybridization buffer, and dehydrated in absolute ethanol. Eight nanograms of biotinylated PPA or somatostatin probe was deposited on the slide and hybridized overnight at 400C through the emulsion. After rinsing, sections were incubated for 1 hr with streptavidin/alkaline phosphatase, diluted 1:75 (Bethesda Research Laboratories), and appropriate substrate (nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate; Bethesda Research Laboratories) and then mounted without counterstaining as described (27) .
RESULTS
Topography and Morphological Characteristics of the Neurons Expressing the D1 Receptor Gene. Autoradiography on x-ray film after hybridization with the D1 probe demonstrated labeling in the caudate-putamen, accumbens nucleus, and olfactory tubercle (Fig. 1) . Microautoradiographic analysis demonstrated clusters of labeled medium-sized neurons (10) (11) (12) (13) (14) (15) Ium in diameter) all over the extent of the caudateputamen and accumbens nucleus (Figs. 1 and 2 A and B). Under standard exposure conditions (3-4 weeks), the largesized neurons (known as acetylcholine neurons; refs. 21 and 28) were not labeled in the striatum (Fig. 2B) . After a long exposure time (6-8 weeks), a significant number (20-30%) of these large-sized neurons showed a weak hybridization signal (0.075 ± 0.020 grain per Am2; mean ± SEM) as compared to that observed over the medium-sized neurons (0.27 ± 0.06 grain per ,um2) (Fig. 2C) . The olfactory tubercle also showed several layers of densely labeled neurons. No reaction was found in the substantia nigra with the D1 probe. Signal specificity was demonstrated by a concentration-dependent decrease of signal after hybridization with an excess of unlabeled D1 probe (20-to 100-fold excess). In the same way, no modification of the signal was found when distinct unlabeled oligonucleotides, including D2 probe, were added to the hybridization buffer (data not shown).
Phenotypical Identification of the Neurons Expressing the D1 Receptor Gene. Comparative analysis on 3-,um adjacent sections of normal rats demonstrated that the D1 and D2 probes labeled separate medium-sized neuronal subsets in the striatum, including the caudate-putamen, the accumbens nucleus, and the olfactory tubercle ( Fig. 3 E and F) on adjacent sections demonstrated that 48% of striatal neurons contained D1 receptor mRNA and 43% contained D2 receptor mRNA. In accordance with these results, combined in situ hybridization in the same section of 6-hydroxydopamine-lesioned rats, with radioactive D1 or D2 probe and biotinylated PPA probe, demonstrated that the neurons containing D1 receptor mRNA were distinct from the ones containing the PPA mRNA (Fig. 3A) . In contrast, the PPA neurons contained D2 receptor mRNA, no matter which striatal region, as described (20) (Fig. 3B) . Comparative analysis on paired 3-,4m sections in normal rats also showed D1 receptor and PPA mRNAs in distinct neurons (Fig. 3 Cand  D) . Comparative analysis on 3-gum paired sections demonstrated that the neurons containing the D1 receptor mRNA contained substance P mRNA in the caudate-putamen and the accumbens nucleus (Fig. 4 A-D) . However, over the extent of the striatum; 15-20% of the neurons containing substance P mRNA did not demonstrate signal with the D1 probe (Fig. 4 A-D) . Simultaneous labeling in the same 10-Itm sections as well as comparative analysis on 3-gm paired sections showed that the largest part of the somatostatin neurons in the striatum was unlabeled with the D1 probe (Fig.  4E) . Nevertheless, a few somatostatin neurons contained detectable D1 mRNA (Fig. 4F) . D2 mRNA was not found in striatal somatostatin neurons (Fig. 4G) .
DISCUSSION
The present results identify the postsynaptic sites of synthesis of D1 receptors in rat striatal neurons. As expected on the basis of pharmacological experiments that have widely described the presence of D1 receptor binding sites in the striatum (10), the D1 receptor gene is expressed in neurons of the caudate-putamen, the accumbens nucleus, and the olfactory tubercle. This result shows that dopamine-responsive neurons are a source ofD1 dopamine receptors in these areas. The specificity of our results is attested by the characteristic localization of labeling in the striatum and by our controls, including Northern blot (data not shown). In addition, these results were confirmed by identical findings with a second D1 oligonucleotide probe (data not shown). No striosome (patch) and matrix compartmentation appears since these neurons (mostly medium-sized) are distributed homogeneously all over the striatum.
Although the overall topography and morphological characteristics of the neurons containing D1 and D2 receptor mRNAs are similar in the forebrain, these receptors are essentially expressed in distinct neuronal subsets in normal and 6-hydroxydopamine-denervated rats, since no overlap was found for D1 and D2 gene expression in the medium-sized neurons, which constitute the largest part of striatal neurons. This result correlates with the ones showing that D1 and D2 receptors are located in striatonigral neurons and in striatopallidal neurons, respectively, which are known to constitute distinct populations (29, 30) , and with the recent observations of Gerfen et al. (31) mine receptors subtypes (32, 33) , our data strongly suggest that the direct effects of dopamine mediated by D1 and D2 receptors on striatal efferent neurons occur on two segregated cell populations. Then, the synergistic effects of D1 and D2 receptor stimulation observed in vivo (12) would be due to actions on distinct target cells in the normal and 6-hydroxydopamine-denervated adult rat striatum. In contrast, recent studies have demonstrated synergistic effects of D1 and D2 stimulation at the level of a single cell in vitro, using acutely dissociated striatal neurons (34) . Compared to the present work, these results could be explained by the activation of unidentified isotypes of dopamine receptors in the same neurons (32, 33) or by qualitative or quantitative changes in dopamine receptor gene expression after the dopamine depletion of the animals and the mechanical disruption of the striatal synaptic connections. Our results also demonstrate that the major site of expression of the D1 receptor gene is the neuronal population that contains substance P as neurotransmitter. This correlates with previous studies that have demonstrated the presence of catecholaminergic terminals on these neurons (35) and changes in substance P peptide and mRNA level after alteration of dopaminergic transmission (36) (37) (38) . Binding studies have also demonstrated D1 receptors present in and synthetized by the striatal neurons projecting to the substantia nigra (pars reticulata) (30) and known to contain substance P (and also t-aminobutyric acid) as neurotransmitters. Our results also correlate with the activation of the protooncogene c-fos specifically in striatonigral projections after D1 stimulation (39) . Since we and others (16) did not find D1 receptor mRNA in the substantia nigra and ventral tegmental area, the D1 receptors present there are probably located on striatonigral fibers as previously postulated (30) . The present data, including the selective presence of D2 receptor mRNA in neurons producing PPA, lead us to postulate that dopamine would act through distinct receptor subtypes-namely, D1 and D2-on distinct efferent striatal neuronal populations (substance P and PPA neurons, respectively). This hypothesis correlates with the opposite effects of a substantia nigra lesion or haloperidol treatment on PPA and substance P gene expression in the striatum (36, 40, 41) . Nevertheless, the coexistence of substance P and enkephalin immunoreactivity in some medium-sized neurons (42, 43) suggests that substance P and PPA genes could be coexpressed in a subpopulation of striatal neurons. In view of the existence of 15-20% of substance P neurons with no detectable D1 receptor mRNA, it is tempting to ask if such neurons could be related, if not identical, to certain neurons containing substance P and enkephalin immunoreactivity simultaneously. Combined The present results demonstrate that the D1 receptor gene is massively expressed, at high level, in efferent striatal neurons. In addition, subpopulations of nonprojecting cholinergic and somatostatinergic neurons appear to express the D1 receptor gene but at a low level. Pharmacological investigations support the hypothesis that dopamine effects on striatal cholinergic neurons are mediated exclusively or predominantly through D2 receptor activation (44, 45) . Such a hypothesis has been substantiated by the presence of D2 receptor mRNA in 80% of striatal cholinergic neurons (21) , but our present results imply that the D1 receptor also contributes to the dopamine effect although to a lesser extent. Somatostatin neurons have also been described to be under dopaminergic influence by using immunohistochemical and in situ hybridization approaches (46, 47) . A direct control of somatostatin neurons by dopamine is not presently substantiated by the absence of D2 receptor mRNA in these neurons and the presence at a low level of D1 receptor mRNA in only a few number of them. It is nevertheless possible that dopamine control of somatostatin neurons involves other unidentified dopamine receptors (32, 33) .
In conclusion, these anatomical studies of dopamine receptor gene expression, including the recent one about the D3 (19) , demonstrate a neurochemical complexity and heterogeneity far more important than previously expected on the basis of dopamine receptor autoradiography. The probable existence of additional dopamine receptor subtypes (32, 33) that could coexist in same neurons, the possible qualitative and quantitative changes in neurotransmitter and receptor gene expression according to experimental conditions including denervation, and the subtle variations in neurotransmitter content according to striosomal and matricial compartments (1, 42) will most probably add to this complexity. Combined use of in situ hybridization, retrograde tracing, and c-fos detection should help to establish the neuroanatomical correlates between the response of chemically identified populations and specific physiological or experimental environments.
